Catheter ablation of atrial fibrillation:: Where do we stand now
被引:0
作者:
Jaïs, P
论文数: 0引用数: 0
h-index: 0
机构:
Hop Cardiol Haut Leveque, F-33604 Pessac, FranceHop Cardiol Haut Leveque, F-33604 Pessac, France
Jaïs, P
[1
]
Haïssaguerre, M
论文数: 0引用数: 0
h-index: 0
机构:
Hop Cardiol Haut Leveque, F-33604 Pessac, FranceHop Cardiol Haut Leveque, F-33604 Pessac, France
Haïssaguerre, M
[1
]
Clémenty, J
论文数: 0引用数: 0
h-index: 0
机构:
Hop Cardiol Haut Leveque, F-33604 Pessac, FranceHop Cardiol Haut Leveque, F-33604 Pessac, France
Clémenty, J
[1
]
机构:
[1] Hop Cardiol Haut Leveque, F-33604 Pessac, France
来源:
ARCHIVES DES MALADIES DU COEUR ET DES VAISSEAUX
|
2001年
/
94卷
/
10期
关键词:
D O I:
暂无
中图分类号:
R5 [内科学];
学科分类号:
1002 ;
100201 ;
摘要:
Atrial fibrillation is the commonest arrhythmia. Besides the risk of complications, a significant number of patients remain symptomatic despite the different antiarrhythmic drugs currently available. The only curative treatment is by surgery or catheter ablation. Since 1994, several approaches have been developed based on two main concepts: modification of the arrhythmogenic substrate by linear lesion to prevent the perpetuation of the arrhythmia and ablation of the foci initiating the atrial fibrillation. The later approach is the most popular one at the moment because the concentration of foci at the site of the pulmonary veins makes it possible to isolate them relatively easily. The presence of atrial foci in some patients complicates matters and limits the success rate to 70%. Despite these limitations and with an acceptable rate of complications, this approach appears preferable to His bundle ablation in young patients with symptomatic paroxysmal atrial fibrillation resistant to antiarrhythmic therapy.